Our pipeline is our engine for growth.

We believe that commitments by the FDA under the Generic Drug User Fee Act (GDUFA) will start to dramatically reshape the generic drug landscape. We count on our Product Development team, as well as external opportunities identified through our Business Development team, to strengthen our pipeline.

We have 32 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $2.0 billion (IMS, November 2017).

View Teligent’s Pipeline